Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Movantik for Opioid-Induced Side Effects After Hip or Knee Surgery
NCT03235739Phase 4Completed
- Sponsor
- Cleveland Clinic
- Start
- Oct 2017
- Primary completion
- May 2021
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of naloxegol in Drug-Induced Urinary Retention, opioid-induced constipation (OIC) and Opioid-induced nausea and vomiting (OINV), sponsored by Cleveland Clinic. Started Oct 2017; status: completed.
02
Drugs
naloxegol
03
Conditions
Drug-Induced Urinary Retentionopioid-induced constipation (OIC)Opioid-induced nausea and vomiting (OINV)
Beyond the preview
Go deeper on NCT03235739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03235739.